ArticleCureus2025
Dyslipidemia Unmasked by the Treatment of Graves' Disease: The Link Between Cholesterol Metabolism and Thyroid Hormones.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid dysfunction can alter serum lipid levels, which can delay the diagnosis of hyperlipidemia. We report the case of a 44-year-old female in whom dyslipidemia was unmasked following the treatment of Graves' disease. The diagnosis of Graves' disease was made after the patient presented with fatigue, weight loss, palpitations, tremors, and shoulder pain. At that time, laboratory testing showed suppressed thyroid-stimulating hormone (TSH), free thyroxine (T4) of 2.39 ng/ml (normal: 0.7-1.48 ng/ml), total triiodothyronine (T3) of 3.36 ng/ml (normal: 0.4-1.93 ng/ml), thyroxine-receptor antibody (TRAb) of 9.07 IU/l (normal: ≤1.75 IU/l), thyroid-stimulating immunoglobulin (TSI) of 7.57 IU/l (normal: ≤0.54 IU/l) and a normal lipid panel (total cholesterol: 140 mg/dl, low-density lipoprotein (LDL) of 79 mg/dl, high-density lipoprotein (HDL) of 43 mg/dl, and triglyceride (TG) of 90 mg/dl). After treatment with methimazole for a year, the patient achieved euthyroidism (TSH: 2.043 mcIU/ml, free T4: 0.93 ng/ml, total T3: 1.28 ng/ml) but had dyslipidemia (total cholesterol: 257 mg/dl, LDL: 174 mg/dl, HDL: 51 mg/dl, TG: 161 mg/dl). There had been no change in the patient's diet or lifestyle. It was thought that improvement in hyperthyroidism had unmasked underlying dyslipidemia. The patient declined statin therapy and chose to pursue stricter lifestyle modifications. The cholesterol panel showed improvement eight months later (total cholesterol: 186 mg/dl, LDL: 114 mg/dl, HDL: 47 mg/dl, TG: 124 mg/dl) with ongoing euthyroidism (TSH: 2.099 mcIU/ml, free T4: 0.97 ng/ml, total T3: 1.24 ng/ml). This report highlights the close relationship between thyroid hormones and cholesterol metabolism. It reviews the pathways through which thyroid hormones affect cholesterol metabolism. The report emphasizes the importance of monitoring lipid profiles in patients with thyroid dysfunction. Conversely, thyroid function testing should be done in patients presenting with lipid abnormalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.